Bio-Rad LaboratoriesBIO
Recorded

Bio-Rad Laboratories 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration34 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Ladies and gentlemen, thank you for standing by. My name is Krista, and I will be your operator today. At this time, I would like to welcome everyone to Bio-Rad's third quarter 2026 results conference call and webcast. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. I would now like to turn the conference over to Ruben Argueta, Bio-Rad's head of investor relations. You may begin. Thank you, operator.

Ruben ArguetaHead of Investor Relations

Good afternoon, everyone, and thank you for joining us. Today, we will review the financial results for the third quarter ended September 30, 2026, and provide an update on key business trends for Bio-Rad. With me on the call today are Norman Schwartz, our chief executive officer, Jon DiVincenzo, president and chief operating officer, and Roop Lakkaraju, executive vice president and chief financial officer. Before we begin our review, I would like to remind everyone that we will be making forward-looking statements about management's goals, plans, and expectations, our future financial performance, and other matters. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Our actual results may differ materially from these plans, goals, and expectations.

Ruben ArguetaHead of Investor Relations

You should not place undue reliance on these forward-looking statements. I encourage you to review our filings with the SEC, where we can discuss in detail the risk factors in our business. The company does not intend to update any forward-looking statements made during the call today. Finally, our remarks today will include references to non-GAAP financials, including net income and diluted earnings per share, which are financial measures that are not defined under generally accepted accounting principles. In addition to excluding certain atypical and non-recurring items, our non-GAAP financial measures exclude changes in the equity value of our stake in Sartorius AG in order to provide investors with a better understanding of Bio-Rad's underlying operational performance. Investors should review the reconciliation of these non-GAAP measures to the comparable GAAP results contained in our earnings release.

Ruben ArguetaHead of Investor Relations

We have also posted a supplemental earnings presentation in the investor relations section of our website for your reference. With that, I will now turn the call over to our chief operating officer, Jon DiVincenzo.

Jon DiVincenzoPresident and COO

Thanks, Ruben. Good afternoon, everyone, and thank you for joining us. The third quarter represented another step forward in our efforts to improve Bio-Rad's operating and financial performance. Total company revenue in the third quarter was approximately $656 million, an increase of 0.5% on a reported basis and 0.7% on a currency-neutral basis compared with the prior year. This marks our first quarter of currency-neutral growth this year. Gross margin expanded to 54.5% on a non-GAAP basis. While the pace of revenue growth remains modest, we are encouraged by the progress across several areas of the business. Clinical diagnostics returned to growth, supported by quality systems and diabetes products. In life science, excluding process chromatography, revenue increased 2.5% year over year.

Jon DiVincenzoPresident and COO

This represents the third consecutive quarter of sequential improvement in the growth rate and was driven by our genomics portfolio, including our Droplet Digital PCR business, led by the QX700 portfolio. ddPCR instrument revenue increased more than 20% for the third consecutive quarter, supported by both conversions from traditional qPCR and competitive wins. We believe these wins are attributable to our expanded portfolio, market-leading assay library, and a simplified workflow. While consumable performance continues to improve, pull-through has not yet normalized, and that could continue into 2027. The pace of our placements over the past year gives us confidence that as those systems ramp to full utilization, pull-through will normalize with them. Longer term, we remain very excited about the opportunity in ddPCR. There are numerous applications for our technology, ranging from biopharma R&D to clinical diagnostics to applied testing, and the penetration remains low.

Jon DiVincenzoPresident and COO

We are confident ddPCR will remain a durable growth driver for Bio-Rad for many years to come. These results demonstrate progress in our business. Turning to some of our key end markets, conditions remain mixed, with encouraging developments in some areas and continued pressure in others. In biopharma, we are seeing signs of improving customer activity. While the recovery remains gradual, we view these trends as constructive for the demand over the coming years. Within process chromatography, revenue has improved sequentially throughout 2026. While we expect a sequential decline in the fourth quarter, 2026 revenue should improve year over year. In the U.S., funding conditions in the academic and government markets remain challenging. NIH outlays declined approximately 15% in the third quarter compared with the prior year and finished the federal fiscal year roughly $6 billion below congressional appropriations.

Jon DiVincenzoPresident and COO

Consistent with this environment, our fourth quarter outlook does not assume a recovery in academic and government end markets. In the United States, we're closely watching the Protecting Access to Medicare Act, or PAMA, which governs Medicare reimbursement rates for certain clinical laboratory tests. Preliminary price rates were published in September, and final rates expected in November. While Bio-Rad is not directly reimbursed under these rates, changes in laboratory reimbursement can influence our customers' economics and purchasing decisions. We have not observed a meaningful change in customer purchasing behavior attributable to the proposed rates to date, and expect any indirect impact on our business in 2027 to be limited. We will continue to evaluate the implications as the final rates become available. Within our APAC region, we saw a return to growth in China in the third quarter.

Jon DiVincenzoPresident and COO

This performance was largely driven by orders that shifted from the second quarter, together with a favorable prior year comparison. The operating environment here remains challenging, with continued preferences for domestic suppliers and pricing pressure affecting the competitive landscape. The National Healthcare Security Administration's updated guidelines continue to create pricing pressure across China's in vitro diagnostics market. Based on our current assessment, we estimate a revenue impact in the middle single-digit millions of dollars in 2027. We are addressing this environment through commercial execution, portfolio management, and cost discipline, while maintaining a measured view of the near-term market outlook. Within EMEA, in the Middle East, our local teams continue to work closely with our customers and supply chain partners to maintain product availability. Logistics costs remain elevated, and our current planning assumptions contemplate continued disruption into 2027.

Jon DiVincenzoPresident and COO

We believe maintaining a realistic set of assumptions is important as we manage through these external challenges. Now turning to our operational priorities, we remain focused on three interconnected objectives: strengthening execution, improving our cost structure, and increasing the productivity across our enterprise. Within our global supply chain, we continue to advance initiatives focused on operational efficiency, procurement, inventory management, and optimization of our manufacturing footprint. These initiatives are important components of our efforts to improve gross margin and build a more efficient operating model. Another important enabler is artificial intelligence. We are approaching AI with two practical objectives: improving how we operate the company and enhancing the products we deliver to our customers. As discussed on the Q2 call, we are applying AI to processes where we believe it can improve productivity, decision-making, and execution. Our focus is on applications that deliver measurable business value.

Jon DiVincenzoPresident and COO

Over time, we expect these efforts, together with the broader organizational improvements, to continue and contribute to productivity. The second opportunity, incorporating AI into our products to improve their capabilities and the value they deliver to our customers, and that brings me to innovation. We continue to make progress in strengthening our product development pipeline and improving the pace at which we bring new solutions to market. During the third quarter, we launched the ChemiDoc Pro Imaging System, our new flagship platform for Western blot imaging. This launch is a tangible example of the benefits of our R&D portfolio prioritization initiated in late 2025. For example, by concentrating resources on selected development programs and improving execution, we were able to accelerate ChemiDoc Pro launch by approximately two quarters.

Jon DiVincenzoPresident and COO

Its analytical algorithm was developed using AI trained on thousands of Western blot images, with the objective of improving the consistency and reliability of image analysis and image interpretation. For customers, these capabilities are designed to enhance confidence in their results and support research productivity. For Bio-Rad, the launch expands our opportunity to serve both existing customers considering system upgrades and new customers seeking advanced imaging capabilities. We also expanded our Foresight Pro pre-packed chromatography column portfolio during the quarter to include our Nuvia resins. This extension broadens the formats available to customers and reflects closer collaboration amongst our product development, marketing, and field application teams. While individual product launches will contribute to growth over time, our broader objective is to establish a more consistent and predictable cadence of innovation across our portfolio.

Jon DiVincenzoPresident and COO

As part of our ongoing portfolio evaluation, we also recorded a non-cash impairment of certain intangible assets during the quarter. We are taking a disciplined approach to evaluating technologies and product programs, including making decisions about where continued investment offers the greatest potential return. Our objective is to improve the return on R&D investments to support revenue growth. In closing, the third quarter provided encouraging evidence of progress. We returned to modest currency-neutral revenue growth, delivered another quarter of strong ddPCR instrument performance, and continued to improve our non-GAAP gross margin, and advanced important organizational and innovation initiatives. Recognizing that our end markets remain uneven, our priorities remain clear: consistent organic growth, improved profitability, and strengthening the execution capabilities of the company. There is more work ahead, but we are encouraged by the progress we are making and remain focused on delivering measurable, sustainable improvements in performance.

Jon DiVincenzoPresident and COO

With that, I will turn the call over to Rup.

Roop LakkarajuEVP and CFO

Thank you, John, and good afternoon. I would like to start with a review of the third quarter 2026 results, then move to guidance. Overall, net sales for the third quarter of 2026 were approximately $656 million on a reported basis, versus $653 million in Q3 of 2025, a year-over-year increase of 0.5%. On a currency-neutral basis, this represents 0.7% year-over-year increase. Life Science sales in the third quarter of 2026 were $255 million, a decrease of 2.8% compared to Q3 of 2025 on a reported basis, and a 2.4% decrease on a currency-neutral basis. This was primarily driven by lower process chromatography sales and ongoing challenges in the academic research market, partially offset by increased ddPCR instrument sales. Excluding process chromatography, Life Science currency-neutral sales increased 2.5%. Currency-neutral sales decreased in the Americas, partially offset by increased sales in EMEA and Asia Pacific and Greater China.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day